Factors predictors neutropenia among patients with cancer receiving FOLFOX 4 chemotherapy regimen
Keywords:
neutropenia, patients with cancer, FOLFOX 4 chemotherapy regimenAbstract
The purpose of this predictive correlational research was to investigate factors predicting neutropenia among patients with cancer receiving FOLFOX 4 chemotherapy regimen. Sample were 76 patients with cancer receiving FOLFOX 4 chemotherapy regimen who received care at a tertiary hospital in Khon Kaen Province. Data were collected by using a demographic information form and a neutropenia risk assessment tool. Descriptive statistics and logistic regressions were used to analyze the data.
The results revealed that the rate of neutropenia was 50%. The majority of neutropenia occurred in the third cycle of chemotherapy. Factors significantly associated with neutropenia were age, body mass index, every one additional cycle of chemotherapy, and history of neutropenia. Factors predicting neutropenia were being 65 years or older (OR = 37.31, 95% CI = 4.02 – 346.75), one additional cycle of chemotherapy had a 61 percent lower risk of developing neutropenia (OR = 0.39, 95% CI = 0.23 - 0.65), and history of neutropenia (OR = 37.14, 95% CI = 4.39 – 314.67). Results from this study can be used to guide in caring for risk monitoring and complication preventing, as well as prevention of neutropenia recurrence among patients with cancer receiving FOLFOX 4 chemotherapy regimen.
References
Smoragiewicz M, Javaheri KR, Yin Y, Gill S. Neutropenia and relative dose intensity on adjuvant FOLFOX chemotherapy are not associated with survival for resected colon cancer. J Gastrointest Cancer 2014; 45(4): 460–5.
Hecht JR, Pillai M, Gollard R, Heim W, Swan F, Patel R, et al. A randomized, placebo-controlled phase Ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastimwithevery-2-weekchemotherapy. Clin Colorectal Cancer [Internet]. 2010; 9(2): 95-101.doi:10.3816/CCC.2010.n.013
Pinter T, Klippel Z, Cesas A, Croitoru A, Decaestecker J, Gibbs P, et al. A phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients receiving first-line FOLFOX/bevacizumab or FOLFIRI/bevacizumab for locally advanced or metastatic colorectal cancer: Final results of the pegfilgrastim and anti-v. Clin Colorectal Cancer [Internet]. 2017; 16(2): 103–14. Available from: http://dx.doi.org/ 10.1016/j.clcc.2016.08.008
Sankoson N. Chemotherapy dosing in special populations: Amputees and obese patients: [Internet]. Khon Kaen: Bangkok Hospital Khon Kaen; 2019 [cited 2019 Jul]. Available from:https://ccpe.pharmacycouncil.org/index. php?option=articledetail& subpage=article_ detail&id=402. (in Thai)
HaghighiS, Kasbkar H, Esmaeilpour K, Yasaei M. Oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) as first line chemotherapy in elderly patients with advanced gastric cancer. Asian Pacific J Cancer Prev 2016; 17(7): 3277–80.
Hong YS, Nam BH, Kim K pyo, Kim JE, Park SJ, Park YS, et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): Anopen-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol [Internet]. 2014; 15(11): 1245–53. Available from: http://dx.doi.org/10.1016/ S1470-2045(14)70377-8.
Qin S, Gong X. Progression of systemic chemotherapy with oxaliplatin-containing regimens for advanced hepatocellular carcinoma in China. Hepatic Oncol 2016; 3(1): 71–81.
Zhao L, Liu R, Zhang Z, Li T, Li F, Liu H, et al. Oxaliplatin/fluorouracil-based adjuvant chemotherapy for locally advanced rectal cancer after neoadjuvant chemoradiotherapy and surgery: A systematic review and meta-analysis of randomized controlled trials. Color Dis 2016; 18(8): 763–72.
Thavichaigarn P. Cancer of colon, rectum and anus. Bankok: Saiturakit Publishing; 2011. (in Thai)
Chu-Yuan H, Jing P, Yi-Sheng W, He-Ping P, Hui Y, Chu-Xiong Z, et al. The impact of chemotherapy-associated neutrophil/lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer. BMC Cancer 2013; 13(177): 1-10.
Schwenkglenks M, Pettengell R, Jackisch C, Paridaens R, Constenla M, Bosly A, et al. Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: Data from the INC-EU prospective observational European neutropenia study. Support Care Cancer 2011; 19(4): 483–90.
Abd el-Rahm an O. Impact of sex on chemotherapy toxicity and efficacy among patients with metastatic colorectal cancer: Pooled analysis of 5 randomized trials. Clin Colorectal Cancer [Internet]. 2019; 18(2): 110-5.e2. Available from: https://doi.org/10. 1016/j.clcc.2018.12.006
Dehghani M, Hafezi N, Vojdani R, Ramzi M. Hematologic toxicities in colorectal cancer patients who received FOLFOX 4. Middle East J Cancer 2015; 6(3): 171-7.
Takenaka Y, Cho H, Yamamoto M, Nakahara S, Yamamoto Y, Inoharaet H. Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Supportive care in cancer: Official Journal of the Multinational Association of Supportive Care in Cancer 2013 21(10): 2861-8. DOI: 10.1007/s00520-013- 1873-9.
Hacibekiroglu I, Kodaz H, Erdogan B, Turkmen E, Esenkaya A, Uzunoglu S, et al. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified folfox6) with advanced gastric cancer patients having a good or poor performance status. Asian Pacific J CancerPrev 2015; 16(6): 2355–9.
Chen C, Chan A, Yap K. Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. J Oncol Pharm Pract 2013; 19(2): 111–20.
Seo SH, Kim S, Kang Y, Ryoo B, Ryu M, Jeong JH. Association of nutritional status-related indices and chemotherapy-induced adverse events in gastric cancer patients. BMC Cancer [Internet]. 2016; 1–9. Available from: http:// dx.doi.org/10.1186/s12885-016-2934-5.
Ratanabunjerdkul H. Association between hypoalbuminemia and severe neutropenia following the first cycle chemotherapy in breast cancer patients. Bangkok: Chulalongkorn university; 2011. (in Thai)
Luepuech A, Danwilai K. Incidence and risk factors of neutropenia in breast cancer patients receiving intravenous chemotherapy at King Chulalongkorn Memorial hospital. TJPP 2017; 9(1): 180-91. (in Thai)
Hashiguchi Y, Kasai M, Fukuda T, Ichimura T, Yasui T, Sumi T. Chemotherapy-induced neutropenia and febrile neutropenia in patients with gynecologic malignancy. Anticancer Drugs 2015; 26(10): 1054–60.
Balducci L. Management of chemotherapy-induced neutropenia in the older cancer patient. Oncology (Williston Park) 2006 Dec; 20 (14 Suppl 9): 26-31. PMID: 17370926
Subongkot S, Saeteaw M, Chanyawong S. Oncology pharmacy practice. Khon Kaen: KKU printing; 2017. (in Thai)
Downloads
Published
How to Cite
Issue
Section
License
The Journal of Nursing Science and Health is copyright holder of published articles. Distributions of articles published in Journal of Nursing Science and Health including online, photocopying which is not for teaching-learning purpose, publication submission elsewhere are prohibited except obtaining permission from the Journal of Nursing Science and Health.
